



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1459  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/774,490	01/31/2001	Shengfang Jin	07334-138001	3043

26161 7590 08/20/2003

FISH & RICHARDSON PC  
225 FRANKLIN ST  
BOSTON, MA 02110

EXAMINER

CANELLA, KAREN A

ART UNIT

PAPER NUMBER

1642

DATE MAILED: 08/20/2003

15

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application N .

09/774,490

Applicant(s)

JIN, SHENGFANG

Examiner

Karen A Canella

Art Unit

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☐ Claim(s) 5-27 is/are pending in the application.
- 4a) Of the above claim(s) 5-22 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) 23-27 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 11. 6) ☐ Other:

Art Unit: 1642

### **DETAILED ACTION**

Acknowledgment is made of applicants election without traverse of Group I

Claim 23 has been amended. Claims 5-27 are pending. Claims 5-22, drawn to non-elected inventions, are withdrawn from consideration.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action.

Claims 23-27 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The first paragraph of 35 U.S.C. 112 states that "the specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same...". The courts have interpreted this to mean that the specification must enable one skilled in the art to make and use the invention without undue experimentation. The courts have further interpreted undue experimentation as requiring "ingenuity beyond that to be expected of one of ordinary skill in the art" (Fields v. Conover, 170 USPQ 276 (CCPA 1971)) or requiring an extended period of experimentation in the absence of sufficient direction or guidance (In re Colianni, 195 USPQ (CCPA 1977)). Additionally the courts have determined that "...where a statement is, on its face, contrary to generally accepted scientific principles", a rejection for failure to teach how to make/or use is proper (In re Marzocchi, 169 USPQ 367 (CCPA 1971)). Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 U.S.C. 112, first paragraph have been described in In re Colianni, 195 USPQ 150, 153 (CCPA 1977) and have been clarified by the Board of Patent Appeals and Interferences in Ex parte Forman, 230 USPQ 546 (BPAI 1986). Among the factor are the nature of the invention, the state of the prior art, the predictability or lack thereof in the art, the amount of direction or guidance present, the presence

Art Unit: 1642

or absence of working examples, the breadth of the claims, and the quantity of experimentation needed. The instant disclosure fails to meet the enablement requirement for the following reasons:

The instant invention has disclosed the correlation between the expression of SEQ ID NO:1 in a cell and the resistance of said cell to drugs. The instant claims are drawn to a method for determining whether a test compound is a candidate compound for modulating drug resistance of an eukaryotic cell the method comprising determining the level of expression of a gene comprising the nucleotide sequence of SEQ ID NO:1 in a eukaryotic cell in the presence and the absence of a test compound and identifying the compound as a candidate modulator of drug resistance of the eukaryotic cell if the level of expression of the gene in the eukaryotic cell in the presence of the test compound differs from the level of expression of the gene in the absence of the test compound. The specification states on page 2, line 31 to page 3, line 10, that the instant invention provides for agents which inhibit or stimulate the activity of the resistance protein or expression. Thus the claims are broadly drawn to encompass the candidate compounds for the upregulation and downregulation or drug resistance. The specification suggests that an antibody which specifically binds to the protein or a antisense nucleic acid can be used to treat a subject having a drug resistance cancer. The specification teaches that a resistance modulator can be a resistance protein or nucleic acid. Thus, the specification is teaching candidate compounds which include the SEQ ID NO:1 and the protein encoded thereby. There are no teachings in the specification nor any art of record which identify a disease or condition which would benefit from the upregulation of SEQ ID NO:1 and the concomitant increase drug-efflux. One of skill in the art would not know how to use a candidate compound identified by the instant method for therapeutic purposes without the identification of a pathological condition which would benefit from the administration of the test compounds which upregulate the activity or expression of SEQ ID NO:1. The specification does not disclose or suggest any other compounds beyond nucleic acids and the protein encoded thereby for the modulation of the resistance gene. Further, the specification is not enabling for how to use antisense nucleic acids or nucleic acids encoding SEQ ID NO:1 in the treatment of drug-resistant cancers or any other disease. The transfer of an antisense construct or vector comprising SEQ ID NO:1 into a patient is in the realm of gene therapy which is unpredictable for the reasons set forth below.

Art Unit: 1642

The instant specification does not teach how to overcome problems with in vivo delivery and expression with respect to the administration of the claimed nucleic acids or viral vectors comprising said nucleic acids. The state of the art as of the priority date sought for the instant application is that in vivo gene delivery is not well developed and is highly unpredictable. For instance Verma et al (Nature, 1997, Vol. 389, pp. 239-242) teach that the Achilles heel of gene therapy is gene delivery. Verma et al state that the ongoing problem is the inability to deliver genes efficiently and to obtain sustained expression (page 239, column 3). Eck et al (Gene-Based Therapy, In: The Pharmacological Basis of Therapeutics, Goodman and Gilman, Ed.s, 1996, pp. 77-101) teach that the fate of the DNA vector itself with regard to the volume of distribution, rate of clearance into tissues etc., the in vivo consequences of altered gene expression and protein function, the fraction of vector taken up by the target cell population, the trafficking of the genetic material within cellular organelles, the rate of degradation of the DNA the level of mRNA produced, the stability of the mRNA produced in vivo, the amount and stability of the protein produced and the proteins compartmentalization or secretory fate within the cell are primary considerations regarding effective therapy. Eck et al state that these factors differ dramatically on the vector used, the protein being produced, and the disease being treated (Eck et al bridging pages 81-82).

As of the priority date sought, it was well known in the art how to infect or transfect cells in vitro or ex vivo with viral vectors. However, using viral vectors to deliver DNA to an organism in vivo, or using infected or transfected cells to deliver nucleic acids which encode a particular protein sequence to an organism in vivo is in the realm of gene therapy, and as of the priority date sought, highly unpredictable in view of the complexity of in vivo systems. Orkin et al state ( "Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy", NIH, 1995) that clinical efficacy had not been definitively demonstrated with any gene therapy protocol (page 1, second paragraph). Orkin et al defines gene therapy as the transfer of DNA into recipient cells either ex vivo or in vivo (page 7, under the heading "Gene transfer"), thus encompassing the instant claims drawn to the administration of antigen presenting cells transfected or infected ex vivo. Orkin et al concludes that, "none of the available vector systems is entirely satisfactory, and many of the perceived advantages of vector systems have not been experimentally validated. Until progress is made in these areas, slow and erratic

Art Unit: 1642

success in applying gene transfer methods to patients can be expected” Orkin et al comment that direct administration of DNA or DNA in liposomes is not well developed and hindered by the low efficiency of gene transfer (page 8, paragraph 5). Orkin et al teach that adequate expression of the transferred genes is essential for therapy, but that in 1995 current data regarding the level and consistency of expression of transferred genes in animal models was unknown. Orkin et al states that in protocols not involving ex vivo infections/transfection, it is necessary to target the expression of the transferred genes to the appropriate tissue or cell type by means of regulatory sequences in gene transfer vectors. The specification does not teach a vector having a specific regulatory sequence which would direct the expression of the nucleic acids within the appropriate tissue type.

The specification does not remedy any of the deficiencies or the prior art with regard to gene therapy. Given the lack of any guidance from the specification on any of the above issues pointed out by Verma or Eck or Orkin. One of skill in the art would be subject to undue experimentation without reasonable expectation of success in order to practice the methods of claims.

Because one of skill in the art would not be able to use antisense nucleic acids or nucleic acids isolated by the instant method claims, one of skill in the art would not be able to use the candidate compounds of the instant invention.

All other rejections and objections as set forth in Paper No. 10. are withdrawn.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Canella whose telephone number is (703) 308-8362. The examiner can normally be reached on Monday through Friday from 8:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa, can be reached on (703) 308-3995. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Application/Control Number: 09/774,490  
Art Unit: 1642

Page 6

Karen A. Canella, Ph.D.  
Patent Examiner, Group 1642  
August 11, 2003

*Karen A. Canella*